THE HYDROXYCHLOROQUINE (HCQ) story got a major plot twist on May 25. Two months after US President Donald Trump waxed eloquent on the benefits of the antimalarial drug in treating Covid-19, the World Health Organization paused the HCQ arm of its multi-centre, multi-drug randomised clinical trial. (Patients who were getting the drug would complete their course, though.) The pause to review safety data from other trials signals that the hype over HCQ was misplaced, and that there is concern about its safety.
The decision, the WHO said, was taken in light of a large observational study published in The Lancet on May 22. The study showed that among one lakh patients from various countries who took the drug (alone or with an antibiotic), the death rate was higher and an increased frequency of irregular heartbeats was observed. Also, the researchers could not confirm any benefit from the drug in Covid-19 patients.
On the same day, the Indian government issued an advisory to expand the pool of personnel who would receive the drug as a preventive measure against the pandemic. The advisory said that cardiovascular side-effects were rare. The basis on which the Centre’s joint task force took this decision included three studies—a retrospective case-control study, an observational study at AIIMS and another investigation from three Central government hospitals—which, as per the advisory, indicated some benefits from taking HCQ for those with high exposure to Covid-19 patients.
This story is from the June 07, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 07, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Between hospital and home
Transitional care centres can add a lot to India's health care system
EFFORT VS EFFECT
The government's attempts to ensure quality drugs is evident, but how well new policies can be monitored on the ground remains to be seen
A way to let go of fear
Accepting the use of adult diapers is a journey with various stages-denial, concealment, rejection and reluctance
Mandeeps & a miracle
Two strangers, one deadly disease and an act of kindness. How Mandeep Mann saved Mandeep Singh, an acute leukaemia patient, by donating his stem cells
The A, B, C of cosmetic surgery
Between eight to 10 lakh cosmetic surgeries happen in India every year. Who is an ideal candidate, and what are the risks and results you can expect?
Vaccines and meningitis
In sub-Saharan Africa, from Senegal in the west to Ethiopia in the east, and encompassing the northern part of Nigeria, there exists a region known as the African Meningitis Belt (AMB).
Celebrating diversity and inclusivity
As Indians battle it out in our nation's 18th general election, it is again time for voters to reflect on the \"Idea of India\"-or rather, on two duelling ideas of India that are now before us and between which the nation must choose at the ballot box.
Defendant: an Hermès handbag
When Hermès was hit with a class-action lawsuit last month for \"antitrust\" activities, it didn't see it coming. Most of the luxury world has all eyes on this suit, filed by two interested consumers who claim they were denied a purchase, and whether it would go to trial.
A legacy, bound
Amal Allana's biography of her father, Ebrahim Alkazi, is as much personal as it is historical
Cutting-edge chronicle
In his new book, Salman Rushdie's pen is mightier than the knife
